TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, reported its results for 2014 today. All resources focused on advancing the allogeneic expanded adipose-derived stem cell product pipeline.
http://ift.tt/1Gj61eT
http://ift.tt/1Gj61eT
No comments:
Post a Comment